drug · small molecule
cabozantinib
pre_registrationupdated 5mo agoby Lotus Pharmaceutical Co Ltd🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 41 investigational indications.
targets
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
all catalysts(0)
nothing on the calendar yet
Trials studying cabozantinib
- phase2A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- phase3Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- phase2Cabozantinib in High Grade Neuroendocrine Neoplasms
- phase2Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
- phase3Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- phase3Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
- phase1Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
- phase1Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
News(2)
- Did Exelixis use a 'trivial' modification to its cash cow to product-hop past a patent cliff? These researchers think soWhen Exelixis CEO Michael Morrissey rolled out the biotech's final numbers for 2025 earlier in the year, there was no mistaking the outsized role that cabozantinib played in funding the company and…endpoints · 1mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 4mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that